a public good project by the
Synthesis
Company
of California

© 2026

Martha Blaney | doi.page

0 works0 citations0 h-index

Martha Blaney

AbbVie (United States)(US)Clinical Trial Investigators(US)

Publications by Year

Research Areas

Advanced Breast Cancer Therapies, Central Venous Catheters and Hemodialysis, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Acute Myocardial Infarction Research

Most-Cited Works

→ Effect of Door-to-Balloon Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction(2006)798 cited
→ Hospital Improvement in Time to Reperfusion in Patients With Acute Myocardial Infarction, 1999 to 2002(2005)229 cited
→ Clinical Characteristics of Dialysis Patients With Acute Myocardial Infarction in the United States(2007)224 cited
→ Achieving Door-to-Balloon Times That Meet Quality Guidelines(2005)204 cited
→ The Pre-Hospital Electrocardiogram and Time to Reperfusion in Patients With Acute Myocardial Infarction, 2000–2002(2006)204 cited
→ Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).(2015)150 cited

→ Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction(2007)

67 cited

→ Door-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI)(2006)62 cited

→ A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer(2017)55 cited

→ Alteplase for the Treatment of Central Venous Catheter Occlusion in Children: Results of a Prospective, Open-label, Single-arm Study (The Cathflo Activase Pediatric Study)(2006)54 cited